Pharmacological Treatment of Oral Lichen Planus: A Review of Evaluated Therapeutics
10.14476/jomp.2025.50.1.6
- Author:
Kun-Hwa KANG
1
;
Ji-Rak KIM
;
Jae-Kwang JUNG
;
Jin-Seok BYUN
Author Information
1. Department of Oral Medicine, School of Dentistry, Kyungpook National University, Daegu, Korea
- Publication Type:Review Article
- From:
Journal of Oral Medicine and Pain
2025;50(1):6-15
- CountryRepublic of Korea
- Language:English
-
Abstract:
Oral lichen planus (OLP) is a chronic inflammatory disease, affecting approximately 0.5% to 2% of the global population. OLP can lead to long-term oral pain, reduced quality of life, with the potential for malignant transformation. Current treatment strategies focus on symptom management and reducing the risk of malignancy. Treatment of OLP is challenging and varies from patient to patient, especially in those who do not respond to corticosteroids. The effectiveness and safety of second-line and third-line treatment options in such cases are continually compared and evaluated, and recently, the application of Janus kinase inhibitors, micro ribonucleic acids, and mesenchymal stem cell-based therapies is being assessed. As a result, the ability of clinicians to select the most appropriate treatment modalities for each patient remains crucial. This review aims to evaluate the efficacy of recent treatment modalities and key considerations to assist clinicians in selecting effective and safe treatment strategies for OLP.
